PSIVIDA CORP.Restricted Stock Unit Agreement • September 13th, 2017 • pSivida Corp. • Laboratory analytical instruments
Contract Type FiledSeptember 13th, 2017 Company IndustrypSivida Corp., a Delaware corporation (the “Company”), hereby grants an Award of Restricted Stock Units to the Participant named below (the “RSUs”). Each RSU represents the right to receive one share of common stock of the Company, par value $0.001 per share (the “Common Stock”), subject to the terms and conditions set forth on this Cover Sheet and in the attached Restricted Stock Unit Agreement (together, the “Agreement”), as well as in the Company’s 2016 Long Term Incentive Plan (as amended from time to time, the “Plan”).
SECOND AMENDED AND RESTATED COLLABORATION AGREEMENT BY AND BETWEEN PSIVIDA US, INC. (f/k/a CONTROL DELIVERY SYSTEMS, INC.) AND ALIMERA SCIENCES, INC. DATED AS OF JULY 10, 2017Collaboration Agreement • September 13th, 2017 • pSivida Corp. • Laboratory analytical instruments • New York
Contract Type FiledSeptember 13th, 2017 Company Industry Jurisdiction
PSIVIDA CORP.Performance-Based Restricted Stock Unit Agreement • September 13th, 2017 • pSivida Corp. • Laboratory analytical instruments
Contract Type FiledSeptember 13th, 2017 Company IndustrypSivida Corp., a Delaware corporation (the “Company”), hereby grants an Award of performance-based Restricted Stock Units to the Participant named below (the “PSUs”). Each PSU represents the right to receive one share of common stock of the Company, par value $0.001 per share (the “Common Stock”), subject to the terms and conditions set forth on this Cover Sheet and in the attached Performance-Based Restricted Stock Unit Agreement (together, the “Agreement”), as well as in the Company’s 2016 Long Term Incentive Plan (as amended from time to time, the “Plan”).
AGREEMENTCollaborative Research and License Agreement • September 13th, 2017 • pSivida Corp. • Laboratory analytical instruments
Contract Type FiledSeptember 13th, 2017 Company IndustryThis Agreement (“Agreement”) is effective as of April 11, 2017 (“Effective Date”), by and between PSIVIDA Corp., PSIVIDA US, Inc., and pSiMedica Limited (collectively, “PSIVIDA”) and PFIZER Inc. (“PFIZER”).